Sector Guides
How to Analyze Diagnostics Stocks in India: RPP, B2C Mix
Team QuartrlyDiagnostic lab earnings in India hinge on Revenue Per Patient and test bundling, not raw test volume — a number that's easy to inflate. Dr. Lal PathLabs and Metropolis Healthcare, India's two largest listed diagnostic chains, report Revenue Per Patient, Samples Per Patient, and B2C revenue mix every quarter because these numbers capture how efficiently a lab turns a single collection-center visit into recurring, higher-margin business. This guide covers RPP, SPP, B2C mix, wellness contribution, patient volume, and test mix — the six metrics that separate a diagnostics network compounding profitably from one padding test counts to look bigger than it is.
Key Takeaways
- Revenue Per Patient (RPP) measures average bill value and pricing power—look for consistent YoY growth above inflation
- Samples Per Patient above 2.5 indicates effective test bundling and package sales
- B2C revenue contribution above 50% signals direct customer ownership and higher margins
- Wellness segment above 15% of revenue provides recurring, non-seasonal income
- Patient Volume is the only reliable growth metric—"test volume" can be inflated through parameter stuffing
Quick Reference
| Metric | Definition | Healthy Range | Warning Sign |
|---|---|---|---|
| Revenue Per Patient (RPP) | Average bill value per patient | >₹800 for leaders, rising YoY | Flat RPP despite volume growth |
| Samples Per Patient (SPP) | Tests conducted per patient visit | >2.5 (bundling effective) | <1.5 (commodity business) |
| B2C Revenue Mix | Direct-to-consumer percentage | >50% of revenue | >70% B2B (margin pressure) |
| Wellness Contribution | Preventive health package revenue | >15% of revenue | 100% acute illness reliance |
| Patient Volume | Unique patients served | 8-12% annual growth | Lagging behind test volume growth |
| Test Mix | Routine vs specialized tests | Growing specialized share | >80% routine (commoditized) |
Understanding Diagnostics Metrics
Diagnostic laboratories differ fundamentally from other healthcare businesses. Their core operations center on logistics—collecting samples from hundreds of collection centers and transporting them to centralized processing hubs. Density of collection network and routing efficiency determine unit economics.
The business model relies on two levers: acquiring patients cost-effectively and maximizing revenue per patient visit through test bundling. A patient walking in for a single fever test represents a loss; convincing that same patient to purchase a comprehensive health package transforms the economics entirely. This is why metrics like Samples Per Patient and Revenue Per Patient matter more than raw test volumes.
Revenue Per Patient (RPP)
What it is: Revenue Per Patient measures the average billing value per patient visit. It is calculated by dividing total revenue by total patient footfall for the period.
Why it matters: RPP indicates both pricing power and the ability to upsell comprehensive test packages. High RPP suggests the lab is attracting patients for premium tests or successfully converting single-test visits into bundled packages.
What good looks like: Leading diagnostic chains maintain RPP above ₹800. Dr. Lal PathLabs reported RPP of ₹889 in Q2 FY26, up 5.4% YoY from ₹844 in Q2 FY25. Metropolis Healthcare typically reports higher RPP due to its focus on metropolitan markets.
Red flag: Flat or declining RPP despite volume growth indicates price discounting or geographic expansion into lower-realization markets (Tier 3-4 towns).
Example from earnings call:
"Revenue per patient for Q2 FY26 came in at Rs. 889, 5.4% higher compared to Rs. 844 in Q2 FY25." — Dr. Lal PathLabs Q2 FY26 Earnings Call
Samples Per Patient (SPP)
What it is: Samples Per Patient measures the average number of distinct tests conducted per patient visit. It reflects the effectiveness of test bundling and package sales.
Why it matters: Higher SPP indicates successful upselling of comprehensive health packages rather than single-test transactions. Since patient acquisition costs are fixed, additional samples per visit generate incremental margin with minimal added expense.
What good looks like: A ratio above 2.5 indicates healthy bundling efficiency. Dr. Lal PathLabs reported 3.09 samples per patient in Q2 FY26, up from 2.94 in Q2 FY25—representing 5% growth in bundling efficiency.
Red flag: SPP near 1.0-1.5 suggests the lab operates as a commodity single-test provider with limited pricing power and vulnerability to competition.
Example from earnings call:
"Samples per patient for Q2 FY26 stood at 3.09 versus 2.94 in Q2 last year, registering a growth of 5%." — Dr. Lal PathLabs Q2 FY26 Earnings Call
B2C vs B2B Revenue Mix
What it is: This metric measures the proportion of revenue from direct-to-consumer patients (walk-ins and home collections) versus institutional clients (hospitals and doctor referrals). B2B revenue typically involves referral commissions paid to doctors.
Why it matters: B2C revenue carries higher margins since no referral fees are paid. It also represents "owned" customer relationships—patients who trust the brand directly are less price-sensitive and more likely to return.
What good looks like: B2C contribution above 50% indicates strong brand equity and direct customer ownership. Metropolis Healthcare reported 59% B2C revenue in Q2 FY26, driven by their TruHealth wellness segment.
Red flag: B2B contribution exceeding 70-80% suggests the lab functions as a backend vendor rather than a consumer brand. Such companies face margin pressure when hospitals demand lower rates.
Example from earnings call:
"Our B2C segment contributed 59% of total revenues for the quarter. This double-digit growth was driven by strong performance in our TruHealth and specialty segments." — Metropolis Healthcare Q2 FY26 Earnings Call
Wellness Revenue Contribution
What it is: Wellness revenue refers to preventive health checkup packages purchased by healthy individuals, as opposed to diagnostic tests ordered by doctors for symptomatic patients. These are typically branded annual health packages.
Why it matters: Wellness revenue is voluntary, high-ticket, and recurring. It smooths earnings volatility from seasonal illness patterns (monsoon-driven dengue, winter respiratory infections) and represents predictable annual revenue.
What good looks like: Branded wellness packages contributing above 15% of total revenue indicates a diversified revenue base. Dr. Lal PathLabs' Swasth-Fit program contributed 26% to Q2 FY26 revenues. Metropolis positions TruHealth as a premium offering.
Red flag: Over-reliance on acute illness testing (100% symptomatic patients) creates seasonal volatility and unpredictable quarterly performance.
Example from earnings call:
"Our flagship Swasth-Fit program contributed 26% to Q2 revenues. As an affordable, bundled preventive health checkup package, it is the key to securing B2C market access." — Dr. Lal PathLabs Q2 FY26 Earnings Call
Patient Volume
What it is: Patient Volume measures the total number of unique patients served during a period. It represents actual footfall across all collection centers and home collection visits.
Why it matters: Patient Volume is the most reliable indicator of organic business growth. Unlike "test volume," which can be manipulated through parameter counting methods, patient volume represents actual human beings using the service.
What good looks like: Consistent patient volume growth of 8-12% annually, supported by network expansion and brand building. Growth should correlate with collection center additions and geographic expansion.
Red flag: Test volume growing significantly faster than patient volume may indicate "parameter stuffing"—counting sub-parameters of single machine runs as separate tests to inflate metrics.
Test Mix: Routine vs Specialized
What it is: Test mix refers to the proportion of revenue from basic routine tests (blood glucose, hemogram, lipid profile) versus specialized tests (molecular diagnostics, genetic testing, histopathology).
Why it matters: Routine tests are commoditized with thin margins and intense price competition. Specialized tests offer higher realizations and create competitive moats through technical expertise and equipment investments.
What good looks like: Growing contribution from specialized segments—molecular diagnostics, cancer markers, prenatal screening—indicates evolution toward higher-margin services. Companies investing in specialized testing capabilities typically command premium valuations.
Red flag: Revenue dominated by routine tests (>80%) with no specialized testing investment leaves the company vulnerable to price wars from aggregator platforms and smaller local labs.
Common Investor Pitfalls
Parameter Stuffing
A common practice in diagnostics marketing involves inflating "test counts" by listing every sub-parameter as a separate test. A standard hemogram is one machine run producing 15 data points (RBC count, WBC count, platelets, hemoglobin, etc.). Ethical reporting counts this as one test; aggressive marketing lists it as 15 separate tests.
When evaluating diagnostic companies, investors should focus on Patient Volume rather than Test Volume. Patient count represents actual human footfall and cannot be manipulated. If a company reports rapid test volume growth but flat patient volume and declining revenue per test, the numbers likely reflect parameter inflation rather than genuine business expansion.
Related Sectors
- Hospital KPIs — diagnostics and hospital chains share the same referral economics and payor-mix pressures.
- General Insurance KPIs — health insurance claims and TPA reimbursement shape B2B diagnostics volumes at hospital-linked labs.